Evidence of protection against clinical and chronic hepatitis B infection 20 years after infant vaccination in a high endemicity region
Vaccination against hepatitis B virus (HBV) immediately after birth prevents neonatal infection by vertical transmission from HBV carrier mothers. There is an ongoing debate whether infant vaccination is sufficient to protect against infection when exposed to HBV later in life. We studied 222 Thai i...
Saved in:
| Published in | Journal of viral hepatitis Vol. 18; no. 5; pp. 369 - 375 |
|---|---|
| Main Authors | , , , , , , |
| Format | Journal Article |
| Language | English |
| Published |
Oxford, UK
Blackwell Publishing Ltd
01.05.2011
|
| Subjects | |
| Online Access | Get full text |
Cover
Loading…
| Abstract | Vaccination against hepatitis B virus (HBV) immediately after birth prevents neonatal infection by vertical transmission from HBV carrier mothers. There is an ongoing debate whether infant vaccination is sufficient to protect against infection when exposed to HBV later in life. We studied 222 Thai infants born to HBsAg −/+ and HBeAg −/+ mothers who were vaccinated with recombinant hepatitis B vaccine at 0‐1‐2‐12 months of age. A subset of 100 subjects received a booster dose at age 5 years. Blood samples collected yearly for 20 years were examined for anti‐HBs antibodies and serological markers of hepatitis B infection (anti‐HBc, HBsAg, and in selected cases HBeAg, anti‐HBe, HBV DNA). During the 20‐year follow‐up, no subject acquired new chronic HBV infection or clinical hepatitis B disease. During the first decade, possible subclinical breakthrough HBV infection (anti‐HBc seroconversion) was only observed in subjects born to HBsAg +/HBeAg + mothers (6/49 [12.2%]). During the second decade, breakthrough HBV infections were detected in all groups (18/140 [12.8%]). Increases in anti‐HBs concentrations that were unrelated to additional HBV vaccination or infection were detected in approximately 10% of subjects in each decade. Primary infant vaccination with a recombinant hepatitis B vaccine confers long‐term protection against clinical disease and new chronic hepatitis B infection despite confirmed hepatitis B exposure. (http://www.clinicaltrials.gov NCT00240500 and NCT00456625) |
|---|---|
| AbstractList | Vaccination against hepatitis B virus (HBV) immediately after birth prevents neonatal infection by vertical transmission from HBV carrier mothers. There is an ongoing debate whether infant vaccination is sufficient to protect against infection when exposed to HBV later in life. We studied 222 Thai infants born to HBsAg −/+ and HBeAg −/+ mothers who were vaccinated with recombinant hepatitis B vaccine at 0‐1‐2‐12 months of age. A subset of 100 subjects received a booster dose at age 5 years. Blood samples collected yearly for 20 years were examined for anti‐HBs antibodies and serological markers of hepatitis B infection (anti‐HBc, HBsAg, and in selected cases HBeAg, anti‐HBe, HBV DNA). During the 20‐year follow‐up, no subject acquired new chronic HBV infection or clinical hepatitis B disease. During the first decade, possible subclinical breakthrough HBV infection (anti‐HBc seroconversion) was only observed in subjects born to HBsAg +/HBeAg + mothers (6/49 [12.2%]). During the second decade, breakthrough HBV infections were detected in all groups (18/140 [12.8%]). Increases in anti‐HBs concentrations that were unrelated to additional HBV vaccination or infection were detected in approximately 10% of subjects in each decade. Primary infant vaccination with a recombinant hepatitis B vaccine confers long‐term protection against clinical disease and new chronic hepatitis B infection despite confirmed hepatitis B exposure. (http://www.clinicaltrials.gov NCT00240500 and NCT00456625) Vaccination against hepatitis B virus (HBV) immediately after birth prevents neonatal infection by vertical transmission from HBV carrier mothers. There is an ongoing debate whether infant vaccination is sufficient to protect against infection when exposed to HBV later in life. We studied 222 Thai infants born to HBsAg -/+ and HBeAg -/+ mothers who were vaccinated with recombinant hepatitis B vaccine at 0-1-2-12 months of age. A subset of 100 subjects received a booster dose at age 5 years. Blood samples collected yearly for 20 years were examined for anti-HBs antibodies and serological markers of hepatitis B infection (anti-HBc, HBsAg, and in selected cases HBeAg, anti-HBe, HBV DNA). During the 20-year follow-up, no subject acquired new chronic HBV infection or clinical hepatitis B disease. During the first decade, possible subclinical breakthrough HBV infection (anti-HBc seroconversion) was only observed in subjects born to HBsAg +/HBeAg + mothers (6/49 [12.2%]). During the second decade, breakthrough HBV infections were detected in all groups (18/140 [12.8%]). Increases in anti-HBs concentrations that were unrelated to additional HBV vaccination or infection were detected in approximately 10% of subjects in each decade. Primary infant vaccination with a recombinant hepatitis B vaccine confers long-term protection against clinical disease and new chronic hepatitis B infection despite confirmed hepatitis B exposure.Vaccination against hepatitis B virus (HBV) immediately after birth prevents neonatal infection by vertical transmission from HBV carrier mothers. There is an ongoing debate whether infant vaccination is sufficient to protect against infection when exposed to HBV later in life. We studied 222 Thai infants born to HBsAg -/+ and HBeAg -/+ mothers who were vaccinated with recombinant hepatitis B vaccine at 0-1-2-12 months of age. A subset of 100 subjects received a booster dose at age 5 years. Blood samples collected yearly for 20 years were examined for anti-HBs antibodies and serological markers of hepatitis B infection (anti-HBc, HBsAg, and in selected cases HBeAg, anti-HBe, HBV DNA). During the 20-year follow-up, no subject acquired new chronic HBV infection or clinical hepatitis B disease. During the first decade, possible subclinical breakthrough HBV infection (anti-HBc seroconversion) was only observed in subjects born to HBsAg +/HBeAg + mothers (6/49 [12.2%]). During the second decade, breakthrough HBV infections were detected in all groups (18/140 [12.8%]). Increases in anti-HBs concentrations that were unrelated to additional HBV vaccination or infection were detected in approximately 10% of subjects in each decade. Primary infant vaccination with a recombinant hepatitis B vaccine confers long-term protection against clinical disease and new chronic hepatitis B infection despite confirmed hepatitis B exposure. Vaccination against hepatitis B virus (HBV) immediately after birth prevents neonatal infection by vertical transmission from HBV carrier mothers. There is an ongoing debate whether infant vaccination is sufficient to protect against infection when exposed to HBV later in life. We studied 222 Thai infants born to HBsAg -/+ and HBeAg -/+ mothers who were vaccinated with recombinant hepatitis B vaccine at 0-1-2-12 months of age. A subset of 100 subjects received a booster dose at age 5 years. Blood samples collected yearly for 20 years were examined for anti-HBs antibodies and serological markers of hepatitis B infection (anti-HBc, HBsAg, and in selected cases HBeAg, anti-HBe, HBV DNA). During the 20-year follow-up, no subject acquired new chronic HBV infection or clinical hepatitis B disease. During the first decade, possible subclinical breakthrough HBV infection (anti-HBc seroconversion) was only observed in subjects born to HBsAg +/HBeAg + mothers (6/49 [12.2%]). During the second decade, breakthrough HBV infections were detected in all groups (18/140 [12.8%]). Increases in anti-HBs concentrations that were unrelated to additional HBV vaccination or infection were detected in approximately 10% of subjects in each decade. Primary infant vaccination with a recombinant hepatitis B vaccine confers long-term protection against clinical disease and new chronic hepatitis B infection despite confirmed hepatitis B exposure. Vaccination against hepatitis B virus (HBV) immediately after birth prevents neonatal infection by vertical transmission from HBV carrier mothers. There is an ongoing debate whether infant vaccination is sufficient to protect against infection when exposed to HBV later in life. We studied 222 Thai infants born to HBsAg −/+ and HBeAg −/+ mothers who were vaccinated with recombinant hepatitis B vaccine at 0‐1‐2‐12 months of age. A subset of 100 subjects received a booster dose at age 5 years. Blood samples collected yearly for 20 years were examined for anti‐HBs antibodies and serological markers of hepatitis B infection (anti‐HBc, HBsAg, and in selected cases HBeAg, anti‐HBe, HBV DNA). During the 20‐year follow‐up, no subject acquired new chronic HBV infection or clinical hepatitis B disease. During the first decade, possible subclinical breakthrough HBV infection (anti‐HBc seroconversion) was only observed in subjects born to HBsAg +/HBeAg + mothers (6/49 [12.2%]). During the second decade, breakthrough HBV infections were detected in all groups (18/140 [12.8%]). Increases in anti‐HBs concentrations that were unrelated to additional HBV vaccination or infection were detected in approximately 10% of subjects in each decade. Primary infant vaccination with a recombinant hepatitis B vaccine confers long‐term protection against clinical disease and new chronic hepatitis B infection despite confirmed hepatitis B exposure. ( http://www.clinicaltrials.gov NCT00240500 and NCT00456625) |
| Author | Leroux-Roels, G. Jacquet, J.-M. Kuriyakose, S. Poovorawan, Y. Chongsrisawat, V. Theamboonlers, A. Leyssen, M. |
| Author_xml | – sequence: 1 givenname: Y. surname: Poovorawan fullname: Poovorawan, Y. organization: Department of Pediatrics, Faculty of Medicine, Center of Excellence in Clinical Virology, Chulalongkorn University, Bangkok, Thailand – sequence: 2 givenname: V. surname: Chongsrisawat fullname: Chongsrisawat, V. organization: Department of Pediatrics, Faculty of Medicine, Center of Excellence in Clinical Virology, Chulalongkorn University, Bangkok, Thailand – sequence: 3 givenname: A. surname: Theamboonlers fullname: Theamboonlers, A. organization: Department of Pediatrics, Faculty of Medicine, Center of Excellence in Clinical Virology, Chulalongkorn University, Bangkok, Thailand – sequence: 4 givenname: G. surname: Leroux-Roels fullname: Leroux-Roels, G. organization: Center for Vaccinology, Ghent University and Hospital, De Pintelaan, Ghent, Belgium – sequence: 5 givenname: S. surname: Kuriyakose fullname: Kuriyakose, S. organization: GlaxoSmithKline Biologicals, Rixensart, Belgium – sequence: 6 givenname: M. surname: Leyssen fullname: Leyssen, M. organization: GlaxoSmithKline Biologicals, Rixensart, Belgium – sequence: 7 givenname: J.-M. surname: Jacquet fullname: Jacquet, J.-M. organization: GlaxoSmithKline Biologicals, Rixensart, Belgium |
| BackLink | https://www.ncbi.nlm.nih.gov/pubmed/20384962$$D View this record in MEDLINE/PubMed |
| BookMark | eNqNUctuEzEUtVARfcAvIO9YTerHzHiyAAnaklBVsCmwtO54PInDxE5tJyS7Sqz4Tb4ET5KGx6r2wtc-95zre88pOrLOaoQwJQOa1vlsQHlZZKwa8gEj6ZVQTtlg_QSdHICjPi5YRgqSH6PTEGYkZbGCPkPHjPAqH5bsBP28WplGW6Wxa_HCu6hVNM5imICxIWLVGWsUdBhsg9XUu3TDU72AaKIJ-B02tt1TGPl1_2OjwQcMbdS-h8BGvAKljIVtjknKeGomU6xto-dGmbjBXk8S9hw9baEL-sX-PEOf31_dXoyzm0-jDxdvbzJVCMGyhvG6LlklSqIJBQ4lp6mxvKYqzwuuhkKJpiJ1wkTDh5A2ZwKAlpDah4afoTc73cWynutGaRs9dHLhzRz8Rjow8l_EmqmcuJXklJKqzJPAq72Ad3dLHaKcm6B014HVbhlkVVJGSlZUKfPl36UONR7G_-cvyrsQvG5lGsh2Uqmy6SQlsvdbzmRvq-xtlb3fcuu3XCeB6j-BhxqPoL7eUb-bTm8ezZPXX8Z9lPjZjm9C1OsDH_w3WQouCvn140iOR7eX4vJaJLHf-7rUCQ |
| CitedBy_id | crossref_primary_10_1016_j_vaccine_2016_10_016 crossref_primary_10_1542_peds_2013_0718 crossref_primary_10_1016_j_ijid_2017_11_008 crossref_primary_10_1080_21645515_2015_1041687 crossref_primary_10_1007_s00430_014_0373_y crossref_primary_10_1155_2012_948059 crossref_primary_10_1016_j_vaccine_2021_08_020 crossref_primary_10_1016_j_ajic_2019_03_008 crossref_primary_10_1186_1471_2458_14_991 crossref_primary_10_1590_S0080_623420140000100011 crossref_primary_10_4161_hv_26269 crossref_primary_10_1097_MD_0000000000005625 crossref_primary_10_4161_hv_24844 crossref_primary_10_3917_spub_175_0751 crossref_primary_10_1016_j_vaccine_2012_02_021 crossref_primary_10_1016_j_vaccine_2017_06_063 crossref_primary_10_3390_vaccines10020267 crossref_primary_10_1016_j_vaccine_2018_01_062 crossref_primary_10_1371_journal_pone_0037707 crossref_primary_10_1111_trf_12902 crossref_primary_10_3390_ph17060807 crossref_primary_10_3390_vaccines12040439 crossref_primary_10_1007_s00105_010_2032_6 crossref_primary_10_3389_fmicb_2020_01526 crossref_primary_10_1016_j_isci_2023_108427 crossref_primary_10_4161_hv_19989 crossref_primary_10_4103_ijmr_IJMR_1852_16 crossref_primary_10_1586_erv_11_151 crossref_primary_10_1086_676865 crossref_primary_10_1016_j_jve_2020_100003 crossref_primary_10_3390_ijerph120403979 crossref_primary_10_2957_kanzo_57_554 crossref_primary_10_1590_1413_81232015217_16862015 crossref_primary_10_1186_1743_422X_10_239 crossref_primary_10_1016_j_vaccine_2018_02_039 crossref_primary_10_1111_hepr_13470 crossref_primary_10_5812_hepatmon_22223 crossref_primary_10_1002_hep_26462 crossref_primary_10_1128_CVI_00539_10 crossref_primary_10_5812_hepatmon_40492 crossref_primary_10_1007_s00705_019_04369_9 crossref_primary_10_1097_PG9_0000000000000046 crossref_primary_10_1371_journal_pone_0025130 crossref_primary_10_1016_j_vaccine_2021_08_086 crossref_primary_10_1186_s40064_015_0813_1 crossref_primary_10_1007_s00761_011_2191_9 crossref_primary_10_1093_infdis_jis943 crossref_primary_10_1080_14760584_2017_1338569 crossref_primary_10_1371_journal_pone_0150499 crossref_primary_10_1186_s12879_022_07854_w crossref_primary_10_2147_IJGM_S472609 crossref_primary_10_1097_INF_0000000000000315 crossref_primary_10_1371_journal_pone_0262126 crossref_primary_10_4103_1995_7645_326255 crossref_primary_10_1080_21645515_2017_1397243 crossref_primary_10_1016_j_cld_2016_06_001 crossref_primary_10_1111_jvh_12263 crossref_primary_10_1016_j_vaccine_2016_10_025 crossref_primary_10_1007_s00705_012_1251_9 crossref_primary_10_1016_j_bjid_2019_10_001 crossref_primary_10_1038_s41598_024_84854_7 crossref_primary_10_4161_hv_29521 crossref_primary_10_1080_21645515_2019_1673119 crossref_primary_10_1371_journal_pone_0202637 crossref_primary_10_1007_s13312_018_1227_2 crossref_primary_10_1016_j_vaccine_2012_10_101 crossref_primary_10_1016_j_vaccine_2015_12_033 crossref_primary_10_1089_vim_2023_0121 crossref_primary_10_1016_j_vaccine_2017_07_040 crossref_primary_10_1097_QCO_0b013e328357e65c crossref_primary_10_1099_jmm_0_001274 crossref_primary_10_1586_14787210_2015_1019867 crossref_primary_10_5812_hepatmon_17263 crossref_primary_10_3748_wjg_v28_i31_4249 crossref_primary_10_1016_j_ajg_2012_02_003 |
| Cites_doi | 10.1016/j.tmaid.2006.04.004 10.1016/j.vaccine.2009.01.027 10.1097/00006454-199210000-00002 10.1016/j.vaccine.2009.10.074 10.1001/jama.1989.03420220092033 10.1016/j.jinf.2008.08.008 10.1016/j.vaccine.2008.09.056 10.1016/j.vaccine.2007.09.013 10.1371/journal.pone.0000753 10.1128/JCM.40.6.1972-1976.2002 10.1016/S0264-410X(02)00358-4 10.1007/s00430-004-0231-4 10.1136/fn.77.1.F47 10.1046/j.1440-1746.2000.0150121356.x 10.1016/0264-410X(90)90237-G 10.1111/j.1365-3156.2006.01709.x 10.1016/j.vaccine.2008.09.034 10.1093/epirev/mxj010 10.1089/vim.2008.0087 |
| ContentType | Journal Article |
| Copyright | 2010 Blackwell Publishing Ltd 2010 Blackwell Publishing Ltd. Copyright © 2011 Blackwell Publishing Ltd 2011 |
| Copyright_xml | – notice: 2010 Blackwell Publishing Ltd – notice: 2010 Blackwell Publishing Ltd. – notice: Copyright © 2011 Blackwell Publishing Ltd 2011 |
| DBID | BSCLL 24P AAYXX CITATION CGR CUY CVF ECM EIF NPM 7X8 5PM |
| DOI | 10.1111/j.1365-2893.2010.01312.x |
| DatabaseName | Istex Wiley Online Library Open Access CrossRef Medline MEDLINE MEDLINE (Ovid) MEDLINE MEDLINE PubMed MEDLINE - Academic PubMed Central (Full Participant titles) |
| DatabaseTitle | CrossRef MEDLINE Medline Complete MEDLINE with Full Text PubMed MEDLINE (Ovid) MEDLINE - Academic |
| DatabaseTitleList | MEDLINE - Academic MEDLINE CrossRef |
| Database_xml | – sequence: 1 dbid: 24P name: Wiley Online Library Open Access url: https://authorservices.wiley.com/open-science/open-access/browse-journals.html sourceTypes: Publisher – sequence: 2 dbid: NPM name: PubMed url: https://proxy.k.utb.cz/login?url=http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?db=PubMed sourceTypes: Index Database – sequence: 3 dbid: EIF name: MEDLINE url: https://proxy.k.utb.cz/login?url=https://www.webofscience.com/wos/medline/basic-search sourceTypes: Index Database |
| DeliveryMethod | fulltext_linktorsrc |
| Discipline | Medicine Biology |
| EISSN | 1365-2893 |
| EndPage | 375 |
| ExternalDocumentID | PMC3110864 20384962 10_1111_j_1365_2893_2010_01312_x JVH1312 ark_67375_WNG_HGTD7DJ7_1 |
| Genre | article Clinical Trial Journal Article |
| GeographicLocations | Thailand |
| GeographicLocations_xml | – name: Thailand |
| GroupedDBID | --- .3N .GA .GJ .Y3 05W 0R~ 10A 1OB 1OC 29L 31~ 33P 36B 3SF 4.4 50Y 50Z 51W 51X 52M 52N 52O 52P 52R 52S 52T 52U 52V 52W 52X 53G 5GY 5HH 5LA 5VS 66C 702 7PT 8-0 8-1 8-3 8-4 8-5 8UM 930 A01 A03 AAESR AAEVG AAHHS AAKAS AANLZ AAONW AASGY AAXRX AAZKR ABCQN ABCUV ABDBF ABEML ABJNI ABPVW ABQWH ABXGK ACAHQ ACBWZ ACCFJ ACCZN ACGFO ACGFS ACGOF ACMXC ACPOU ACPRK ACSCC ACXBN ACXQS ADBBV ADBTR ADEOM ADIZJ ADKYN ADMGS ADOZA ADXAS ADZCM ADZMN AEEZP AEGXH AEIGN AEIMD AENEX AEQDE AEUQT AEUYR AFBPY AFEBI AFFPM AFGKR AFPWT AFZJQ AHBTC AHEFC AHMBA AIACR AITYG AIURR AIWBW AJBDE ALAGY ALMA_UNASSIGNED_HOLDINGS ALUQN AMBMR AMYDB ASPBG ATUGU AVWKF AZBYB AZFZN AZVAB BAFTC BDRZF BFHJK BHBCM BMXJE BROTX BRXPI BSCLL BY8 C45 CAG COF CS3 D-6 D-7 D-E D-F DCZOG DPXWK DR2 DRFUL DRMAN DRSTM DTERQ DU5 EAD EAP EAS EBC EBD EBS EBX EJD EMB EMK EMOBN EPT ESX EX3 F00 F01 F04 F5P FEDTE FUBAC FZ0 G-S G.N GODZA H.X HF~ HGLYW HVGLF HZI HZ~ IHE IX1 J0M K48 KBYEO LATKE LC2 LC3 LEEKS LH4 LITHE LOXES LP6 LP7 LUTES LW6 LYRES MEWTI MK4 MRFUL MRMAN MRSTM MSFUL MSMAN MSSTM MXFUL MXMAN MXSTM N04 N05 N9A NF~ O66 O9- OIG OVD P2W P2X P2Z P4B P4D PALCI PQQKQ Q.N Q11 QB0 Q~Q R.K RIWAO RJQFR ROL RX1 SAMSI SUPJJ SV3 TEORI TUS UB1 V8K W8V W99 WBKPD WHWMO WIH WIJ WIK WOHZO WOW WQJ WRC WUP WVDHM WXI WXSBR XG1 YFH YUY ZZTAW ~IA ~WT 24P AAHQN AAIPD AAMMB AAMNL AANHP AAYCA ACRPL ACUHS ACYXJ ADNMO AEFGJ AEYWJ AFWVQ AGHNM AGQPQ AGXDD AGYGG AIDQK AIDYY ALVPJ AAYXX CITATION CGR CUY CVF ECM EIF NPM 7X8 5PM |
| ID | FETCH-LOGICAL-c5772-d23bb628760e01a3a6310014b1c4453c97c7d80b01a7d39a9a9327aa16a013ad3 |
| IEDL.DBID | DR2 |
| ISSN | 1352-0504 1365-2893 |
| IngestDate | Thu Aug 21 18:04:30 EDT 2025 Fri Jul 11 12:41:01 EDT 2025 Mon Jul 21 05:55:42 EDT 2025 Tue Jul 01 03:39:39 EDT 2025 Thu Apr 24 22:57:23 EDT 2025 Wed Aug 20 07:26:06 EDT 2025 Wed Oct 30 09:50:32 EDT 2024 |
| IsDoiOpenAccess | true |
| IsOpenAccess | true |
| IsPeerReviewed | true |
| IsScholarly | true |
| Issue | 5 |
| Language | English |
| License | http://onlinelibrary.wiley.com/termsAndConditions#vor 2010 Blackwell Publishing Ltd. Re-use of this article is permitted in accordance with the Creative Commons Deed, Attribution 2.5, which does not permit commercial exploitation. |
| LinkModel | DirectLink |
| MergedId | FETCHMERGED-LOGICAL-c5772-d23bb628760e01a3a6310014b1c4453c97c7d80b01a7d39a9a9327aa16a013ad3 |
| Notes | istex:50AEB6041357361DE6BD88033F346D9F009FC11B ArticleID:JVH1312 ark:/67375/WNG-HGTD7DJ7-1 http://wileyonlinelibrary.com/onlineopen#OnlineOpen_Terms Re‐use of this article is permitted in accordance with the Terms and Conditions set out at ObjectType-Article-2 SourceType-Scholarly Journals-1 ObjectType-Feature-1 content type line 23 |
| OpenAccessLink | https://proxy.k.utb.cz/login?url=https://onlinelibrary.wiley.com/doi/abs/10.1111%2Fj.1365-2893.2010.01312.x |
| PMID | 20384962 |
| PQID | 861206258 |
| PQPubID | 23479 |
| PageCount | 7 |
| ParticipantIDs | pubmedcentral_primary_oai_pubmedcentral_nih_gov_3110864 proquest_miscellaneous_861206258 pubmed_primary_20384962 crossref_citationtrail_10_1111_j_1365_2893_2010_01312_x crossref_primary_10_1111_j_1365_2893_2010_01312_x wiley_primary_10_1111_j_1365_2893_2010_01312_x_JVH1312 istex_primary_ark_67375_WNG_HGTD7DJ7_1 |
| ProviderPackageCode | CITATION AAYXX |
| PublicationCentury | 2000 |
| PublicationDate | May 2011 |
| PublicationDateYYYYMMDD | 2011-05-01 |
| PublicationDate_xml | – month: 05 year: 2011 text: May 2011 |
| PublicationDecade | 2010 |
| PublicationPlace | Oxford, UK |
| PublicationPlace_xml | – name: Oxford, UK – name: England |
| PublicationTitle | Journal of viral hepatitis |
| PublicationTitleAlternate | J Viral Hepat |
| PublicationYear | 2011 |
| Publisher | Blackwell Publishing Ltd |
| Publisher_xml | – name: Blackwell Publishing Ltd |
| References | World Health Organization. Progress in the control of viral hepatitis: memorandum from a WHO meeting. Bull World Health Organ 1988; 66: 443-455. Su FH, Cheng SH, Li CY et al. Hepatitis B seroprevalence and anamnestic response amongst Taiwanese young adults with full vaccination in infancy, 20 years subsequent to national hepatitis B vaccination. Vaccine 2007; 25: 8085-8090. But DY, Lai CL, Lim WL, Fung J, Wong DK, Yuen MF. Twenty-two years follow-up of a prospective randomized trial of hepatitis B vaccines without booster dose in children: final report. Vaccine 2008; 26: 6587-6591. Wichajarn K, Kosalaraksa P, Wiangnon S. Incidence of hepatocellular carcinoma in children in Khon Kaen before and after national hepatitis B vaccine program. Asian Pac J Cancer Prev 2008; 9: 507-510. Lopez VA, Bourne EJ, Lutz MW, Condreay LD. Assessment of the COBAS Amplicor HBV Monitor Test for quantitation of serum hepatitis B virus DNA levels. J Clin Microbiol 2002; 40: 1972-1976. van der Sande MA, Waight PA, Mendy M et al. Long-term protection against HBV chronic carriage of Gambian adolescents vaccinated in infancy and immune response in HBV booster trial in adolescence. PLoS ONE 2007; 2: e753. Poovorawan Y, Chongsrisawat V, Tangkijvanich P. Problems and prevention of viral hepatitis in Thailand. J Med Assoc Thai 2001; 84(Suppl 1): S18-S25. Lolekha S, Warachit B, Hirunyachote A, Bowonkiratikachorn P, West DJ, Poerschke G. Protective efficacy of hepatitis B vaccine without HBIG in infants of HBeAg-positive carrier mothers in Thailand. Vaccine 2002; 20: 3739-3743. Poovorawan Y, Chongsrisawat V, Theamboonlers A, Bock HL, Leyssen M, Jacquet JM. Persistence of antibodies and immune memory to hepatitis B vaccine 20 years after infant vaccination in Thailand. Vaccine 2010; 28: 730-736. Poovorawan Y, Sanpavat S, Pongpunlert W et al. Comparison of a recombinant DNA hepatitis B vaccine alone or in combination with hepatitis B immune globulin for the prevention of perinatal acquisition of hepatitis B carriage. Vaccine 1990; 8(Suppl): S56-S59. Alfaleh F, Alshehri S, Alansari S et al. Long-term protection of hepatitis B vaccine in Saudi Arabia 18 years after vaccination. J Infect 2008; 57: 404-409. Poovorawan Y, Sanpavat S, Chumdermpadetsuk S, Safary A. Long-term hepatitis B vaccine in infants born to hepatitis B e antigen positive mothers. Arch Dis Child Fetal Neonatal Ed 1997; 77: F47-F51. Ng KP, Saw TL, Baki A, Rozainah K, Pang KW, Ramanathan M. Impact of the Expanded Program of Immunization against hepatitis B infection in school children in Malaysia. Med Microbiol Immunol (Berl) 2005; 194: 163-168. Chinchai T, Chirathaworn C, Praianantathavorn K et al. Long-term humoral and cellular immune response to hepatitis B vaccine in high-risk children 18-20 years after neonatal immunization. Viral Immunol 2009; 22: 125-130. Van Damme P, Van Herck K. A review of the long-term protection after hepatitis A and B vaccination. Travel Med Infect Dis. 2007; 5: 79-84. World Health Organization. Hepatitis B vaccines WHO position paper. Wkly Epidemiol Rec 2004; 79: 255-263. Kao JT, Wang JH, Hung CH et al. Long-term efficacy of plasma-derived and recombinant hepatitis B vaccines in a rural township of Central Taiwan. Vaccine 2009; 27: 1858-1862. Chongsrisawat V, Yoocharoen P, Theamboonlers A et al. Hepatitis B seroprevalence in Thailand: 12 years after hepatitis B vaccine integration into the national expanded programme on immunization. Trop Med Int Health 2006; 11: 1496-1502. Zanetti AR, Van Damme P, Shouval D. The global impact of vaccination against hepatitis B: a historical overview. Vaccine 2008; 26: 6266-6273. Poovorawan Y, Sanpavat S, Pongpunlert W, Chumdermpadetsuk S, Sentrakul P, Safary A. Protective efficacy of a recombinant DNA hepatitis B vaccine in neonates of HBe antigen-positive mothers. JAMA 1989; 261: 3278-3281. Poovorawan Y, Sanpavat S, Pongpunglert W et al. Long term efficacy of hepatitis B vaccine in infants born to hepatitis B e antigen-positive mothers. Pediatr Infect Dis J 1992; 11: 816-821. Merican I, Guan R, Amarapuka D et al. Chronic hepatitis B virus infection in Asian countries. J Gastroenterol Hepatol 2000; 15: 1356-1361. Chien YC, Jan CF, Kuo HS, Chen CJ. Nationwide hepatitis B vaccination program in Taiwan: effectiveness in the 20 years after it was launched. Epidemiol Rev 2006; 28: 126-135. 2009; 22 2005; 194 1997; 77 2000; 15 2002; 20 2006; 11 2010; 28 2002; 40 2006; 28 2004; 79 2008; 9 1988; 66 2008; 26 1989; 261 2008; 57 2007; 5 2007; 2 1992; 11 1990; 8 2001; 84 2009; 27 2007; 25 e_1_2_7_5_2 Wichajarn K (e_1_2_7_11_2) 2008; 9 World Health Organization (e_1_2_7_2_2) 2004; 79 e_1_2_7_9_2 e_1_2_7_8_2 e_1_2_7_7_2 e_1_2_7_6_2 e_1_2_7_19_2 Poovorawan Y (e_1_2_7_4_2) 2001; 84 e_1_2_7_18_2 e_1_2_7_17_2 e_1_2_7_16_2 e_1_2_7_15_2 e_1_2_7_14_2 e_1_2_7_24_2 e_1_2_7_12_2 e_1_2_7_23_2 e_1_2_7_22_2 World Health Organization (e_1_2_7_3_2) 1988; 66 e_1_2_7_10_2 e_1_2_7_21_2 e_1_2_7_20_2 Poovorawan Y (e_1_2_7_13_2) 1989; 261 |
| References_xml | – reference: van der Sande MA, Waight PA, Mendy M et al. Long-term protection against HBV chronic carriage of Gambian adolescents vaccinated in infancy and immune response in HBV booster trial in adolescence. PLoS ONE 2007; 2: e753. – reference: Su FH, Cheng SH, Li CY et al. Hepatitis B seroprevalence and anamnestic response amongst Taiwanese young adults with full vaccination in infancy, 20 years subsequent to national hepatitis B vaccination. Vaccine 2007; 25: 8085-8090. – reference: Alfaleh F, Alshehri S, Alansari S et al. Long-term protection of hepatitis B vaccine in Saudi Arabia 18 years after vaccination. J Infect 2008; 57: 404-409. – reference: Chongsrisawat V, Yoocharoen P, Theamboonlers A et al. Hepatitis B seroprevalence in Thailand: 12 years after hepatitis B vaccine integration into the national expanded programme on immunization. Trop Med Int Health 2006; 11: 1496-1502. – reference: Zanetti AR, Van Damme P, Shouval D. The global impact of vaccination against hepatitis B: a historical overview. Vaccine 2008; 26: 6266-6273. – reference: Poovorawan Y, Sanpavat S, Pongpunlert W et al. Comparison of a recombinant DNA hepatitis B vaccine alone or in combination with hepatitis B immune globulin for the prevention of perinatal acquisition of hepatitis B carriage. Vaccine 1990; 8(Suppl): S56-S59. – reference: Chinchai T, Chirathaworn C, Praianantathavorn K et al. Long-term humoral and cellular immune response to hepatitis B vaccine in high-risk children 18-20 years after neonatal immunization. Viral Immunol 2009; 22: 125-130. – reference: But DY, Lai CL, Lim WL, Fung J, Wong DK, Yuen MF. Twenty-two years follow-up of a prospective randomized trial of hepatitis B vaccines without booster dose in children: final report. Vaccine 2008; 26: 6587-6591. – reference: Van Damme P, Van Herck K. A review of the long-term protection after hepatitis A and B vaccination. Travel Med Infect Dis. 2007; 5: 79-84. – reference: Poovorawan Y, Chongsrisawat V, Tangkijvanich P. Problems and prevention of viral hepatitis in Thailand. J Med Assoc Thai 2001; 84(Suppl 1): S18-S25. – reference: Lopez VA, Bourne EJ, Lutz MW, Condreay LD. Assessment of the COBAS Amplicor HBV Monitor Test for quantitation of serum hepatitis B virus DNA levels. J Clin Microbiol 2002; 40: 1972-1976. – reference: Merican I, Guan R, Amarapuka D et al. Chronic hepatitis B virus infection in Asian countries. J Gastroenterol Hepatol 2000; 15: 1356-1361. – reference: Poovorawan Y, Sanpavat S, Pongpunlert W, Chumdermpadetsuk S, Sentrakul P, Safary A. Protective efficacy of a recombinant DNA hepatitis B vaccine in neonates of HBe antigen-positive mothers. JAMA 1989; 261: 3278-3281. – reference: Poovorawan Y, Chongsrisawat V, Theamboonlers A, Bock HL, Leyssen M, Jacquet JM. Persistence of antibodies and immune memory to hepatitis B vaccine 20 years after infant vaccination in Thailand. Vaccine 2010; 28: 730-736. – reference: Poovorawan Y, Sanpavat S, Pongpunglert W et al. Long term efficacy of hepatitis B vaccine in infants born to hepatitis B e antigen-positive mothers. Pediatr Infect Dis J 1992; 11: 816-821. – reference: Kao JT, Wang JH, Hung CH et al. Long-term efficacy of plasma-derived and recombinant hepatitis B vaccines in a rural township of Central Taiwan. Vaccine 2009; 27: 1858-1862. – reference: Chien YC, Jan CF, Kuo HS, Chen CJ. Nationwide hepatitis B vaccination program in Taiwan: effectiveness in the 20 years after it was launched. Epidemiol Rev 2006; 28: 126-135. – reference: World Health Organization. Hepatitis B vaccines WHO position paper. Wkly Epidemiol Rec 2004; 79: 255-263. – reference: Ng KP, Saw TL, Baki A, Rozainah K, Pang KW, Ramanathan M. Impact of the Expanded Program of Immunization against hepatitis B infection in school children in Malaysia. Med Microbiol Immunol (Berl) 2005; 194: 163-168. – reference: World Health Organization. Progress in the control of viral hepatitis: memorandum from a WHO meeting. Bull World Health Organ 1988; 66: 443-455. – reference: Lolekha S, Warachit B, Hirunyachote A, Bowonkiratikachorn P, West DJ, Poerschke G. Protective efficacy of hepatitis B vaccine without HBIG in infants of HBeAg-positive carrier mothers in Thailand. Vaccine 2002; 20: 3739-3743. – reference: Wichajarn K, Kosalaraksa P, Wiangnon S. Incidence of hepatocellular carcinoma in children in Khon Kaen before and after national hepatitis B vaccine program. Asian Pac J Cancer Prev 2008; 9: 507-510. – reference: Poovorawan Y, Sanpavat S, Chumdermpadetsuk S, Safary A. Long-term hepatitis B vaccine in infants born to hepatitis B e antigen positive mothers. Arch Dis Child Fetal Neonatal Ed 1997; 77: F47-F51. – volume: 261 start-page: 3278 year: 1989 end-page: 3281 article-title: Protective efficacy of a recombinant DNA hepatitis B vaccine in neonates of HBe antigen‐positive mothers publication-title: JAMA – volume: 77 start-page: F47 year: 1997 end-page: F51 article-title: Long‐term hepatitis B vaccine in infants born to hepatitis B e antigen positive mothers publication-title: Arch Dis Child Fetal Neonatal Ed – volume: 79 start-page: 255 year: 2004 end-page: 263 article-title: Hepatitis B vaccines WHO position paper publication-title: Wkly Epidemiol Rec – volume: 9 start-page: 507 year: 2008 end-page: 510 article-title: Incidence of hepatocellular carcinoma in children in Khon Kaen before and after national hepatitis B vaccine program publication-title: Asian Pac J Cancer Prev – volume: 5 start-page: 79 year: 2007 end-page: 84 article-title: A review of the long‐term protection after hepatitis A and B vaccination publication-title: Travel Med Infect Dis. – volume: 15 start-page: 1356 year: 2000 end-page: 1361 article-title: Chronic hepatitis B virus infection in Asian countries publication-title: J Gastroenterol Hepatol – volume: 20 start-page: 3739 year: 2002 end-page: 3743 article-title: Protective efficacy of hepatitis B vaccine without HBIG in infants of HBeAg‐positive carrier mothers in Thailand publication-title: Vaccine – volume: 11 start-page: 816 year: 1992 end-page: 821 article-title: Long term efficacy of hepatitis B vaccine in infants born to hepatitis B e antigen‐positive mothers publication-title: Pediatr Infect Dis J – volume: 8 start-page: S56 issue: Suppl year: 1990 end-page: S59 article-title: Comparison of a recombinant DNA hepatitis B vaccine alone or in combination with hepatitis B immune globulin for the prevention of perinatal acquisition of hepatitis B carriage publication-title: Vaccine – volume: 2 start-page: e753 year: 2007 article-title: Long‐term protection against HBV chronic carriage of Gambian adolescents vaccinated in infancy and immune response in HBV booster trial in adolescence publication-title: PLoS ONE – volume: 66 start-page: 443 year: 1988 end-page: 455 article-title: Progress in the control of viral hepatitis: memorandum from a WHO meeting publication-title: Bull World Health Organ – volume: 40 start-page: 1972 year: 2002 end-page: 1976 article-title: Assessment of the COBAS Amplicor HBV Monitor Test for quantitation of serum hepatitis B virus DNA levels publication-title: J Clin Microbiol – volume: 27 start-page: 1858 year: 2009 end-page: 1862 article-title: Long‐term efficacy of plasma‐derived and recombinant hepatitis B vaccines in a rural township of Central Taiwan publication-title: Vaccine – volume: 26 start-page: 6587 year: 2008 end-page: 6591 article-title: Twenty‐two years follow‐up of a prospective randomized trial of hepatitis B vaccines without booster dose in children: final report publication-title: Vaccine – volume: 84 start-page: S18 issue: Suppl 1 year: 2001 end-page: S25 article-title: Problems and prevention of viral hepatitis in Thailand publication-title: J Med Assoc Thai – volume: 25 start-page: 8085 year: 2007 end-page: 8090 article-title: Hepatitis B seroprevalence and anamnestic response amongst Taiwanese young adults with full vaccination in infancy, 20 years subsequent to national hepatitis B vaccination publication-title: Vaccine – volume: 11 start-page: 1496 year: 2006 end-page: 1502 article-title: Hepatitis B seroprevalence in Thailand: 12 years after hepatitis B vaccine integration into the national expanded programme on immunization publication-title: Trop Med Int Health – volume: 194 start-page: 163 year: 2005 end-page: 168 article-title: Impact of the Expanded Program of Immunization against hepatitis B infection in school children in Malaysia publication-title: Med Microbiol Immunol (Berl) – volume: 28 start-page: 126 year: 2006 end-page: 135 article-title: Nationwide hepatitis B vaccination program in Taiwan: effectiveness in the 20 years after it was launched publication-title: Epidemiol Rev – volume: 57 start-page: 404 year: 2008 end-page: 409 article-title: Long‐term protection of hepatitis B vaccine in Saudi Arabia 18 years after vaccination publication-title: J Infect – volume: 28 start-page: 730 year: 2010 end-page: 736 article-title: Persistence of antibodies and immune memory to hepatitis B vaccine 20 years after infant vaccination in Thailand publication-title: Vaccine – volume: 26 start-page: 6266 year: 2008 end-page: 6273 article-title: The global impact of vaccination against hepatitis B: a historical overview publication-title: Vaccine – volume: 22 start-page: 125 year: 2009 end-page: 130 article-title: Long‐term humoral and cellular immune response to hepatitis B vaccine in high‐risk children 18–20 years after neonatal immunization publication-title: Viral Immunol – volume: 9 start-page: 507 year: 2008 ident: e_1_2_7_11_2 article-title: Incidence of hepatocellular carcinoma in children in Khon Kaen before and after national hepatitis B vaccine program publication-title: Asian Pac J Cancer Prev – volume: 66 start-page: 443 year: 1988 ident: e_1_2_7_3_2 article-title: Progress in the control of viral hepatitis: memorandum from a WHO meeting publication-title: Bull World Health Organ – ident: e_1_2_7_12_2 doi: 10.1016/j.tmaid.2006.04.004 – ident: e_1_2_7_23_2 doi: 10.1016/j.vaccine.2009.01.027 – volume: 84 start-page: S18 issue: 1 year: 2001 ident: e_1_2_7_4_2 article-title: Problems and prevention of viral hepatitis in Thailand publication-title: J Med Assoc Thai – volume: 79 start-page: 255 year: 2004 ident: e_1_2_7_2_2 article-title: Hepatitis B vaccines WHO position paper publication-title: Wkly Epidemiol Rec – ident: e_1_2_7_16_2 doi: 10.1097/00006454-199210000-00002 – ident: e_1_2_7_18_2 doi: 10.1016/j.vaccine.2009.10.074 – volume: 261 start-page: 3278 year: 1989 ident: e_1_2_7_13_2 article-title: Protective efficacy of a recombinant DNA hepatitis B vaccine in neonates of HBe antigen‐positive mothers publication-title: JAMA doi: 10.1001/jama.1989.03420220092033 – ident: e_1_2_7_21_2 doi: 10.1016/j.jinf.2008.08.008 – ident: e_1_2_7_7_2 doi: 10.1016/j.vaccine.2008.09.056 – ident: e_1_2_7_20_2 doi: 10.1016/j.vaccine.2007.09.013 – ident: e_1_2_7_22_2 doi: 10.1371/journal.pone.0000753 – ident: e_1_2_7_19_2 doi: 10.1128/JCM.40.6.1972-1976.2002 – ident: e_1_2_7_6_2 doi: 10.1016/S0264-410X(02)00358-4 – ident: e_1_2_7_10_2 doi: 10.1007/s00430-004-0231-4 – ident: e_1_2_7_15_2 doi: 10.1136/fn.77.1.F47 – ident: e_1_2_7_5_2 doi: 10.1046/j.1440-1746.2000.0150121356.x – ident: e_1_2_7_14_2 doi: 10.1016/0264-410X(90)90237-G – ident: e_1_2_7_8_2 doi: 10.1111/j.1365-3156.2006.01709.x – ident: e_1_2_7_24_2 doi: 10.1016/j.vaccine.2008.09.034 – ident: e_1_2_7_9_2 doi: 10.1093/epirev/mxj010 – ident: e_1_2_7_17_2 doi: 10.1089/vim.2008.0087 |
| SSID | ssj0013251 |
| Score | 2.2946694 |
| Snippet | Vaccination against hepatitis B virus (HBV) immediately after birth prevents neonatal infection by vertical transmission from HBV carrier mothers. There is an... |
| SourceID | pubmedcentral proquest pubmed crossref wiley istex |
| SourceType | Open Access Repository Aggregation Database Index Database Enrichment Source Publisher |
| StartPage | 369 |
| SubjectTerms | Adolescent Carrier State - epidemiology Carrier State - immunology Carrier State - prevention & control Child Child, Preschool DNA, Viral - blood efficacy Endemic Diseases - prevention & control Female hepatitis B Hepatitis B Antibodies - blood Hepatitis B e Antigens - blood Hepatitis B e Antigens - immunology Hepatitis B Surface Antigens - blood Hepatitis B Surface Antigens - immunology Hepatitis B Vaccines - administration & dosage Hepatitis B Vaccines - immunology Hepatitis B virus - genetics Hepatitis B virus - immunology Hepatitis B virus - pathogenicity Hepatitis B, Chronic - epidemiology Hepatitis B, Chronic - immunology Hepatitis B, Chronic - prevention & control Hepatitis B, Chronic - virology Humans Immunization, Secondary Infant Infant, Newborn Infectious Disease Transmission, Vertical - prevention & control Longitudinal Studies Male Original Pregnancy Pregnancy Complications, Infectious - immunology Pregnancy Complications, Infectious - virology Thailand - epidemiology vaccine Young Adult |
| Title | Evidence of protection against clinical and chronic hepatitis B infection 20 years after infant vaccination in a high endemicity region |
| URI | https://api.istex.fr/ark:/67375/WNG-HGTD7DJ7-1/fulltext.pdf https://onlinelibrary.wiley.com/doi/abs/10.1111%2Fj.1365-2893.2010.01312.x https://www.ncbi.nlm.nih.gov/pubmed/20384962 https://www.proquest.com/docview/861206258 https://pubmed.ncbi.nlm.nih.gov/PMC3110864 |
| Volume | 18 |
| hasFullText | 1 |
| inHoldings | 1 |
| isFullTextHit | |
| isPrint | |
| link | http://utb.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwrV1Lj9MwELZgVyAuPJZXeFQ-IG6pHCexk-OW0q0q7QqhXdibNXbS3aqQom2KtpyQOPE3-SXM5KUW9rBCKJcqrpN6OmPPjD9_w9irQLgklSLzARKFAYqyPi6CU184mEo1xWZHqYHDIzU-iSan8WmDf6KzMDU_RJdwI8uo5msycLDLbSOvEFq44DYIrSAMZJ_8SWog_-i93NhQiOvYK5a-iEW0Deq58kFbK9UuCf3yKjf0bzTlppdbLVOje2zeDrBGp8z7q9L23bc_uB__jwTus7uNN8v3a_V7wG7kxR67Vde3XO-x24fNzv1D9rMtX8oXU96QQ6BKcDiDGXqovD2hyaHIuKsZe_l5TnjvcrbkA96ixgouxa_vP9ZooUteVTinJtQP_hUcvqvSNLzFgRMVM6cU_2f8EeWaUxGKRfGInYzeHr8Z-00ZCN_F6Pv7mQytVRjZKZGLAEJQtCkRRDZwURSHLtVOZwkldEFnYQp4hVIDBApQIJCFj9lOsSjyp4yr1AI4bcOcaNQSbXWOE1ruUhtIKSD2mG7_cuMajnQq1fHJbMRKKHNDMjckc1PJ3Fx6LOh6fql5Qq7R53WlVV0HuJgTzk7H5uPRgRkfHA_1cKJN4DHeqp1B66ctHSjyxWppEnRQBYawicee1FrYPUyKMIlSJXFMW_rZfYGIxbdbitl5RTAe0tkQFXlMVep37QGZyYcxfXr2rx2fszt1zp4ApS_YTnmxyl-i01faHrspo3c9trs_GA5Gvcq4fwN0akqL |
| linkProvider | Wiley-Blackwell |
| linkToHtml | http://utb.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwrV1Lb9NAEF6hVkAvPAoF89wD4uZovbZ37SNQ2hCaHFAKva3Ga4dGbR3UOKjhhMSJv8kvYWb9UAI9VAjlYmWzdnb8ze7M7Ow3jL0IhE1SKXIfIFHooKjMx0Vw4gsLE6km2GwpNDAcqf5hNDiKj5pyQHQWpuaH6AJupBluviYFp4D0upa7FC1ccZsUrSAMZA8Nyk0q8O38qw9yZUshrr2vWPoiFtF6Ws-ld1pbqzZJ7BeXGaJ_51Ou2rluodq7zU7bIdb5KSe9RZX17Lc_2B__kwzusFuNQctf1Qi8y64V5Ta7Xpe4XG6zG8Nm8_4e-9lWMOWzCW_4IRAVHD7DFI1U3h7S5FDm3Nakvfy4oJTvajrnr3mbOFZyKX59_7FEJZ1zV-ScmhAi_CtYfJYDG37FgRMbM6co_xn-iWrJqQ7FrLzPDvfejt_0_aYShG9jNP_9XIZZptC5U6IQAYSgaF8iiLLARlEc2lRbnScU0wWdhyngJ5QaIFCAAoE83GEb5awsHjKu0gzA6iwsiEkt0ZkucE4rbJoFUgqIPabbd25sQ5NO1TpOzYq7hDI3JHNDMjdO5ubCY0HX80tNFXKFPi8drLoOcH5CqXY6Np9G-6a_P97VuwNtAo_xFncGJwDa1YGymC3mJkEbVaAXm3jsQQ3D7mZShEmUKoljWgNo9wPiFl9vKafHjmM8pOMhKvKYcvi78oDM4GOfrh79a8fn7GZ_PDwwB-9G7x-zrTqET_mlT9hGdb4onqINWGXPnG7_BuMwTF0 |
| linkToPdf | http://utb.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwrV1Lb9NAEF6hVlRceBQo5rkHxM3Rem3v2kcgpCHQCKEWeluN1zaNAk7VOKjhhMSJv8kvYcYvxdBDhVAuUTZrZyffeGd2v_2GsaeesFEsReoCRAoTFJW4OAnmrrCQS5Vjs6WlgYOpGh8Fk-PwuOE_0VmYWh-iW3Ajz6ie1-Tgp2ned_KKoYUTbsPQ8nxPDjCe3A6UiAjhw_dyY0chrJOvULoiFEGf1XPhlXpT1TZZ_fyiOPRvOuVmmFvNU6MbbN6OsKanzAerMhnYb3-IP_4fE9xk15twlj-v8XeLXcmKXXa1LnC53mU7B83W_W32s61fyhc5b9QhEBMcPsEMQ1TeHtHkUKTc1pK9_CQjwnc5W_IXvKWNFVyKX99_rNFFl7wqcU5NCBD-FSzeq4IafsSBkxYzpzX-L_gjyjWnKhSL4g47Gr06fDl2mzoQrg0x-HdT6SeJwtROiUx44IOiXQkvSDwbBKFvY211GtGKLujUjwFfvtQAngI0CKT-XbZVLIrsHuMqTgCsTvyMdNQinegMn2iZjRNPSgGhw3T7lxvbiKRTrY7PZiNZQpsbsrkhm5vK5ubcYV7X87QWCrlEn2cVqroOcDYnop0OzcfpvhnvHw71cKKN5zDews6g-9OeDhTZYrU0EUaoAnPYyGF7NQq7i0nhR0GsJI6ph8_uC6Qs3m8pZieVwrhPh0NU4DBVwe_SAzKTD2N6d_9fOz5hO--GI_P29fTNA3atXr8nculDtlWerbJHGACWyePKs38D02pLFQ |
| openUrl | ctx_ver=Z39.88-2004&ctx_enc=info%3Aofi%2Fenc%3AUTF-8&rfr_id=info%3Asid%2Fsummon.serialssolutions.com&rft_val_fmt=info%3Aofi%2Ffmt%3Akev%3Amtx%3Ajournal&rft.genre=article&rft.atitle=Evidence+of+protection+against+clinical+and+chronic+hepatitis+B+infection+20+years+after+infant+vaccination+in+a+high+endemicity+region&rft.jtitle=Journal+of+viral+hepatitis&rft.au=Poovorawan%2C+Y&rft.au=Chongsrisawat%2C+V&rft.au=Theamboonlers%2C+A&rft.au=Leroux-Roels%2C+G&rft.date=2011-05-01&rft.pub=Blackwell+Publishing+Ltd&rft.issn=1352-0504&rft.eissn=1365-2893&rft.volume=18&rft.issue=5&rft.spage=369&rft.epage=375&rft_id=info:doi/10.1111%2Fj.1365-2893.2010.01312.x&rft_id=info%3Apmid%2F20384962&rft.externalDocID=PMC3110864 |
| thumbnail_l | http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/lc.gif&issn=1352-0504&client=summon |
| thumbnail_m | http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/mc.gif&issn=1352-0504&client=summon |
| thumbnail_s | http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/sc.gif&issn=1352-0504&client=summon |